June 5, 2026 · 13 min read
Ozempic, Wegovy, Mounjaro, Zepbound — the GLP-1 drug class may be the most important pharmaceutical investment theme of this decade. With a US addressable market of 100 million patients, Medicare Part D coverage starting January 2026, and next-generation molecules pushing weight loss beyond 20%, this sector is transforming from a niche diabetes play into a defining healthcare megatrend. Here is how to analyse the key stocks, the pipeline, and where the real risks lie.
The obesity drug market has scaled faster than almost any pharmaceutical category in history. Eight numbers that capture where things stand right now:
GLP-1 receptor agonists (glucagon-like peptide-1 drugs) were developed as diabetes treatments. Then clinical trials showed they produced substantial, sustained weight loss — and suddenly the addressable market expanded from hundreds of millions of type 2 diabetes patients to over a billion people globally who are clinically obese.
The scale of this market is genuinely transformative. Obesity is associated with type 2 diabetes, heart disease, sleep apnoea, joint disease, certain cancers, and many other chronic conditions. A drug that durably treats obesity could be worth hundreds of billions in annual revenue — and the two leading companies (Novo Nordisk and Eli Lilly) are already well on their way.
Unlike many drug categories, GLP-1 drugs have a powerful, well-understood mechanism with a remarkable safety profile accumulated over decades of use. That de-risks the investment thesis considerably compared to early-stage biotech.
GLP-1 (glucagon-like peptide-1) is a naturally occurring gut hormone released after eating. It signals the pancreas to release insulin, tells the liver to reduce glucose output, and — critically — activates receptors in the brain that create a feeling of fullness and reduce appetite. GLP-1 receptor agonists are synthetic molecules that mimic and amplify these effects.
| Drug | Mechanism | Administration | Weight Loss | Approval |
|---|---|---|---|---|
| Wegovy | GLP-1 agonist | Weekly injection | ~15% | FDA 2021 |
| Zepbound | GLP-1 + GIP dual agonist | Weekly injection | ~22% | FDA 2023 |
| Retatrutide | GLP-1 + GIP + Glucagon | Weekly injection | ~24% | Phase 3 (est. 2026) |
| Orforglipron | Oral GLP-1 agonist | Daily oral pill | ~15% | NDA filed 2025 |
| Amycretin | GLP-1 + amylin | Oral pill | ~13% (oral) | Phase 2 |
The investment thesis for GLP-1 drugs extends well beyond weight loss. Every new indication approval expands the addressable market by tens of millions of patients:
Wegovy received FDA approval for cardiovascular risk reduction following the landmark SELECT trial, which showed a 20% reduction in major adverse cardiac events in non-diabetic obese patients. This is a game-changer for insurance coverage.
Zepbound (tirzepatide) became the first drug approved to treat sleep apnea in 2024. The SURMOUNT-OSA trial showed a 63% reduction in apnea-hypopnea index. An entirely new patient population now qualifies for coverage.
Novo Nordisk's FLOW trial showed semaglutide reduced the risk of kidney disease progression by 24% in patients with type 2 diabetes and CKD. CKD affects ~37 million Americans — a massive incremental population.
Early evidence suggests GLP-1 agonists reduce neuroinflammation and tau protein accumulation. Novo Nordisk is running a large Phase 3 trial for semaglutide in Alzheimer's. If positive, this would be transformative.
Emerging data suggests GLP-1 receptors in the brain's reward circuitry reduce craving behaviors. Studies in alcohol use disorder, smoking cessation, and opioid addiction are showing early positive signals.
Both semaglutide and tirzepatide show strong liver fat reduction. With no approved NASH treatments until recently, this represents another 15–20 million patient opportunity in the US alone.
| Metric | NVO — Novo Nordisk | LLY — Eli Lilly |
|---|---|---|
| Market Cap | ~$400B | ~$750B |
| Obesity Drug | Wegovy (semaglutide) | Zepbound (tirzepatide) |
| Diabetes Drug | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
| Quarterly Obesity Rev. | ~$1.7B (Wegovy) | ~$2.5B (Zepbound) |
| YoY Revenue Growth | ~90%+ (Wegovy) | Fastest launch ever |
| Key Pipeline Asset | CagriSema, Amycretin | Retatrutide (~24% loss) |
| Oral GLP-1 | Rybelsus (approved), Amycretin (Ph2) | Orforglipron (NDA filed) |
| Fwd P/E (approx.) | ~22× | ~45× |
| Dividend | Yes (~1.2%) | Yes (~0.6%) |
| Domicile | Denmark (ADR) | United States |
| Other Pipeline | Alzheimer's, CKD, NASH | Alzheimer's (donanemab), oncology |
Novo Nordisk pioneered the modern GLP-1 era. Semaglutide (the active molecule behind Ozempic, Wegovy, and Rybelsus) is the highest-revenue pharmaceutical product in the world. The company generates more than 80% of its revenue from diabetes and obesity drugs, making it the purest-play GLP-1 investment available.
Eli Lilly is executing one of the most impressive commercial ramp-ups in pharmaceutical history. Zepbound became the fastest-ever pharmaceutical product to reach $1B in quarterly revenue. The company's tirzepatide molecule demonstrably outperforms semaglutide in head-to-head trials, and its next-generation pipeline (retatrutide, orforglipron) may give it a sustained clinical edge for the rest of the decade.
Semaglutide GLP-1 agonist. The highest-prescribed GLP-1 drug globally, generating over $15 billion annually. Has become shorthand for the entire GLP-1 drug class despite only being approved for diabetes, not obesity.
Higher-dose version of semaglutide approved specifically for chronic weight management. Produces ~15% average weight loss. SELECT cardiovascular trial approval gives insurers a compelling reimbursement rationale beyond cosmetic weight loss.
Dual GIP and GLP-1 receptor agonist. Clinical trials show superior HbA1c reduction and greater average weight loss than semaglutide, making it Novo Nordisk's most significant competitive threat in diabetes.
Same tirzepatide molecule as Mounjaro, approved for obesity and sleep apnea. SURMOUNT-5 head-to-head trial showed 47% more total body weight loss vs Wegovy. Growing faster than any drug in pharmaceutical history.
First oral GLP-1 approved. Lower weight loss than injectable versions but much easier to administer. Critical for expanding the addressable market to patients who will not self-inject. A stepping stone to the oral obesity pill market.
The next wave of GLP-1 innovation is already in late-stage trials. The race to the best oral pill and the highest weight loss percentages will define competitive positioning for the next five years.
| Company | Drug | Mechanism | Phase | Wt Loss | Key Note |
|---|---|---|---|---|---|
| NVONovo Nordisk | CagriSema | GLP-1 + amylin | Phase 3 | ~22% | Next-gen combo; misses vs expectations but still strong |
| NVONovo Nordisk | Amycretin | GLP-1 + amylin (oral) | Phase 2 | ~13% (oral) | Oral pill format; high investor interest |
| LLYEli Lilly | Orforglipron | Oral GLP-1 agonist | Phase 3 | ~15% | Non-peptide oral; potential mass market breakthrough |
| LLYEli Lilly | Retatrutide | Triple agonist (GLP-1/GIP/Glucagon) | Phase 3 | ~24% | Highest weight loss ever seen in a trial drug |
| AMGNAmgen | MariTide | GLP-1/GIP bispecific antibody | Phase 3 | ~20% | Monthly injection; differentiated dosing schedule |
| PFEPfizer | Danuglipron | Oral GLP-1 agonist | Phase 2b | ~10% | Once-daily oral; formulation improvements underway |
| AZNAstraZeneca | AZD9550 | GLP-1 oral (Structure Tx partnership) | Phase 2 | TBD | AZN partnered with Structure Therapeutics (GPCR) |
| RHHBYRoche | CT-388 | GLP-1/GIP dual agonist | Phase 2 | ~18% | Roche re-entering metabolic disease after gap |
The single biggest constraint on GLP-1 revenue growth for the past three years has not been demand (which is virtually unlimited) but manufacturing capacity. GLP-1 peptides are extraordinarily complex to manufacture — they require sophisticated bioreactors, multiple purification steps, and specialized fill-and-finish facilities capable of filling autoinjector pens at scale.
The compounding pharmacy loophole — where pharmacies could produce copies of semaglutide during the FDA drug shortage period — is closing. The FDA officially removed semaglutide from the drug shortage list in early 2025, and tirzepatide followed. This is a significant tailwind for NVO and LLY as it removes ~$2B+ in annualized compounding competition.
Insurance coverage has been the biggest barrier to GLP-1 adoption. These drugs cost $1,000–$1,300/month at list price in the US. Without coverage, they are unaffordable for most patients. That is changing rapidly.
The CMS Innovation Center launched a model allowing Medicare Part D plans to cover obesity drugs. This is the single biggest US coverage expansion ever — affecting ~65M Medicare beneficiaries.
Major employers including Amazon, Walmart, and JPMorgan now cover GLP-1 drugs. Employers covering GLP-1s rose from 25% in 2023 to over 50% in 2025, driven by SELECT cardiovascular trial data showing long-term cost savings.
The FDA's cardiovascular risk reduction approval for Wegovy gives insurers a clinical (not just lifestyle) rationale for coverage. This has been cited by multiple payers as the trigger for expanding their obesity drug policies.
UK's NHS has expanded semaglutide coverage. Germany, France, and other EU markets are at earlier stages. International coverage expansion is a multi-year revenue driver as cost-effectiveness data accumulates globally.
NVO and LLY currently dominate with 90%+ combined market share. But a wave of well-capitalized competitors is investing heavily to break in, particularly in the oral pill segment where neither company has a fully approved obesity product yet.
The GLP-1 sector is perhaps the clearest large-cap secular growth story in markets today. The addressable market is vast, the clinical evidence is unusually strong, and multiple independent catalysts (new indications, oral formulations, Medicare coverage, international expansion) provide a multiyear runway for above-market growth.
Eli Lilly is the higher-growth, higher-valuation option — best suited to investors who believe tirzepatide's clinical superiority and the company's pipeline depth justify a premium. The stock requires near-flawless execution to justify ~45× forward earnings.
Novo Nordisk is the more conservatively valued option at ~22× forward earnings, with a proven commercial franchise and a deep oral pipeline in amycretin. It offers a better margin of safety but faces more competitive pressure from tirzepatide's superior weight loss efficacy.
For investors who want exposure without single-stock risk, the XLV (Health Care SPDR) or a focused position in both NVO and LLY alongside the competitive landscape (AMGN, CVS, UNH) provides diversified exposure to the theme.
The key question to ask every quarter: how many new patients started therapy, what did net pricing do, and what do the most recent pipeline readouts say about next-generation molecules? Those three metrics will tell you more about long-term value creation than any single quarterly earnings report.
See detailed AI scores, valuation metrics, analyst targets, and investor profiles for every stock in the GLP-1 theme.